

## CME Article

979 **Benign Neoplasms, Mass-Like Infections, and Pseudotumors That Mimic Hepatic Malignancy at MRI**

*Andreu F. Costa, Sharon E. Clarke, Ashley E. Stueck, Matthew D.F. McInnes, and Seng Thipphavong*

## Review Articles

995 **<sup>23</sup>Na-MRI as a Noninvasive Biomarker for Cancer Diagnosis and Prognosis**

*Linda Osei Poku, Yongna Cheng, Kai Wang, and Xilin Sun*

1015 **Artificial Intelligence for MR Image Reconstruction: An Overview for Clinicians**

*Dana J. Lin, Patricia M. Johnson, Florian Knoll, and Yvonne W. Lui*

## Original Research

## Musculoskeletal

1029 **Comparison of MR Ultrashort Echo Time and Optimized 3D-Multiecho In-Phase Sequence to Computed Tomography for Assessment of the Osseous Craniocervical Junction**

*Eva Deininger-Czermak, Christina Villefort, Nikolaus von Knebel Doeberitz, Sabine Franckenberg, Pascal Kälin, David Kenkel, Dominic Gascho, Marco Piccirelli, Tim Finkenstaedt, Michael J. Thali, and Roman Guggenberger*

## Editorial

1040 **Editorial for "Comparison of MR Ultrashort Echo Time and Optimized 3D-Multiecho In-Phase Sequence to Computed Tomography for Assessment of the Osseous Craniocervical Junction"**

*Sikandar Shaikh*

## Chest

1042 **3D Oxygen-Enhanced MRI at 3T MR System: Comparison With Thin-Section CT of Quantitative Capability for Pulmonary Functional Loss Assessment and Clinical Stage Classification of COPD in Smokers**

*Yoshiharu Ohno, Masao Yui, Takeshi Yoshikawa, Shinichiro Seki, Daisuke Takenaka, Yoshimori Kassai, Hidekazu Hattori, Kazuhiro Murayama, and Hiroshi Toyama*

## Editorial

1052 **Editorial for: "3D Oxygen-Enhanced MR Imaging at 3T MR System: Comparison With Thin-Section CT of Quantitative Capability for Pulmonary Functional Loss Assessment and Clinical Stage Classification of COPD in Smokers"**

*Gordon W. Cowell*

## Abdomen

1054 **MRI Texture-Based Models for Predicting Mitotic Index and Risk Classification of Gastrointestinal Stromal Tumors**

*Linsha Yang, Tao Zheng, Yanchao Dong, Zhanqiu Wang, Defeng Liu, Juan Du, Shuo Wu, Qinglei Shi, and Lanxiang Liu*

1066 **Radiomics Analysis Based on Multiparametric MRI for Predicting Early Recurrence in Hepatocellular Carcinoma After Partial Hepatectomy**

*Ying Zhao, Jingjun Wu, Qinhe Zhang, Zhengyu Hua, Wenjing Qi, Nan Wang, Tao Lin, Liuji Sheng, Dahua Cui, Jinghong Liu, Qingwei Song, Xin Li, Tingfan Wu, Yan Guo, Jingjing Cui, and Ailian Liu*

1080 **Radiomics Approaches for Predicting Liver Fibrosis With Nonenhanced T<sub>1</sub>-Weighted Imaging: Comparison of Different Radiomics Models**

*Ming Ni, Lili Wang, Haiyang Yu, Xiaoyi Wen, Yinghua Yang, Guangzhen Liu, Yabin Hu, and Zhiming Li*

- Editorial** 1090 **Editorial for "Radiomics Approaches for Predicting Liver Fibrosis With Nonenhanced T1-Weighted Imaging: Comparison of Different Radiomics Models"**  
*Xucheng Zhu*
- Thoracic** 1092 **Flow Volume Loop and Regional Ventilation Assessment Using Phase-Resolved Functional Lung (PREFUL) MRI: Comparison With <sup>129</sup>Xenon Ventilation MRI and Lung Function Testing**  
*Till F Kaireit, Agilo Kern, Andreas Voskrebenzev, Gesa H Pöhler, Filip Klimes, Lea Behrendt, Marcel Gutberlet, Tawfik Moher-Alsady, Anna-Maria Dittrich, Frank Wacker, Jens Hohlfeld, and Jens Vogel-Claussen*
- Editorial** 1106 **Editorial for "Flow Volume Loop and Regional Ventilation Assessment Using Phase Resolved Functional Lung (PREFUL) MRI: Comparison With <sup>129</sup>Xenon Ventilation MRI and Lung Function Testing"**  
*Rachel L. Eddy and Jonathan H. Rayment*
- Breast** 1108 **Simultaneous Multislice Readout-Segmented Echo Planar Imaging for Diffusion-Weighted MRI in Patients With Invasive Breast Cancers**  
*Sung Eun Song, Ok Hee Woo, Kyu Ran Cho, Bo Kyoung Seo, Yo Han Son, Robert Grimm, Wei Liu, and Woo Kyung Moon*
- Editorial** 1116 **Editorial for "Simultaneous multislice readout-segmented echo planar imaging for diffusion-weighted MR imaging in patients with invasive breast cancers"**  
*Zhuangsheng Liu, Xiaoping Li, and Wansheng Long*
- 1118 **Investigation of Synthetic Relaxometry and Diffusion Measures in the Differentiation of Benign and Malignant Breast Lesions as Compared to BI-RADS**  
*Weibo Gao, Shuqun Zhang, Jinxia Guo, Xiaocheng Wei, Xiaohui Li, Yan Diao, Wei Huang, Yue Yao, Ali Shang, Yanyan Zhang, Quanxin Yang, and Xin Chen*
- Editorial** 1128 **Editorial for "Investigation of synthetic relaxometry and diffusion measures in the differentiation of benign and malignant breast lesions as compared to BI-RADS"**  
*Catherine J. Moran*
- Head and Neck** 1130 **Performance Comparison of Compressed Sensing Algorithms for Accelerating T<sub>1ρ</sub> Mapping of Human Brain**  
*Rajiv G. Menon, Marcelo V.W. Zibetti, Rajan Jain, Yulin Ge, and Ravinder R. Regatte*
- 1140 **Can Arterial Spin Labeling Perfusion Imaging be Used to Differentiate Nasopharyngeal Carcinoma From Nasopharyngeal Lymphoma?**  
*Zongqiong Sun, Shudong Hu, Yuxi Ge, Linfang Jin, Jianfeng Huang, and Weiqiang Dou*
- Editorial** 1149 **Editorial for "Can arterial spin labeling perfusion imaging be used to differentiate nasopharyngeal carcinoma from nasopharyngeal lymphoma?"**  
*Erkan Gökçe*
- Neuro** 1151 **Signal Intensity and Volume of Pituitary and Thyroid Glands in Preterm and Term Infants**  
*Sayo Otani, Yasutaka Fushimi, Kogoro Iwanaga, Seiichi Tomotaki, Yusuke Yokota, Sonoko Oshima, Azusa Sakurama, Krishna Pandu Wicaksono, Takuya Hinoda, Akihiko Sakata, Satoshi Nakajima, Tomohisa Okada, Junko Takita, Masahiko Kawai, and Kaori Togashi*
- 1162 **Quantification of Myelinated Nerve Fraction and Degeneration in Spinal Cord Neuropil by SHIFT MRI**  
*Tatiana Wolfe, Kristopher Hoffman, Matthew K. Hogan, Betsy Salazar, Xiufeng Tang, Lesley Chaboub, Caio C. Quini, Zhong-Lin Lu, and Philip J. Horner*
- 1175 **Evaluating High Spatial Resolution Diffusion Kurtosis Imaging at 3T: Reproducibility and Quality of Fit**  
*Loxlan W. Kasa, Roy A.M. Haast, Tristan K. Kuehn, Farah N. Mushtaha, Corey A. Baron, Terry Peters, and Ali R. Khan*

- Editorial** 1188 **Editorial for "Evaluating High Spatial Resolution Diffusion Kurtosis Imaging at 3T: Reproducibility and Quality of Fit"**  
*Pim Pullens*
- 1190 **Crossed Cerebellar Diaschisis in Patients With Symptomatic Unilateral Anterior Circulation Stroke Is Associated With Hemodynamic Impairment in the Ipsilateral MCA Territory**  
*Martina Sebök, Christiaan Hendrik Bas van Niftrik, Marco Piccirelli, Giovanni Muscas, Athina Pangalu, Susanne Wegener, Christoph Stippich, Luca Regli, and Jorn Fierstra*
- Editorial** 1198 **Editorial for "Crossed Cerebellar Diaschisis in Patients With Symptomatic Unilateral Anterior Circulation Stroke Is Associated With Hemodynamic Impairment in the Ipsilateral MCA Territory"**  
*Paul A. Nyquist*
- 1200 **Changes in Apparent Diffusion Coefficient (ADC) during Cardiac Cycle of the Brain in Idiopathic Normal Pressure Hydrocephalus Before and After Cerebrospinal Fluid Drainage**  
*Tomoshi Osawa, Naoki Ohno, Mitsuhiro Mase, Tosiaki Miyati, Ryoko Omasa, Shota Ishida, Hirohito Kan, Nobuyuki Arai, Harumasa Kasai, Yuta Shibamoto, Satoshi Kobayashi, and Toshifumi Gabata*
- Editorial** 1208 **Editorial for: "ΔADC Analysis of the Brain in Idiopathic Normal Pressure Hydrocephalus Before and After Cerebrospinal Fluid Drainage"**  
*Angelika Barbara Mennecke and Arnd Dörfler*
- Pelvis** 1210 **Optimized MRI Assessment for Clinically Significant Prostate Cancer: A STARD-Compliant Two-Center Study**  
*Jie Bao, Rui Zhi, Ying Hou, Jing Zhang, Chen-Jiang Wu, Xi-Ming Wang, and Yu-Dong Zhang*
- Technical** 1220 **Quantitative Evaluations of Geometrical Distortion Corrections in Cortical Surface-Based Analysis of High-Resolution Functional MRI Data at 7T**  
*Tetsuya Yamamoto, Masaki Fukunaga, Sho K. Sugawara, Yuki H. Hamano, and Norihiro Sadato*
- Editorial** 1235 **Editorial for "Quantitative Evaluations of Geometrical Distortion Corrections in Cortical Surface-Based Analysis of High-Resolution Functional MRI Data at 7T"**  
*Xiaowei Zou*
- 1237 **Whole-Slab 3D MR Spectroscopic Imaging of the Human Brain With Spiral-Out-In Sampling at 7T**  
*Morteza Esmaeili, Bernhard Strasser, Wolfgang Bogner, Philipp Moser, Zhe Wang, and Ovidiu C. Andronesi*
- Editorial** 1251 **Editorial for "Whole-Slab 3D MR Spectroscopic Imaging of the Human Brain With Spiral-Out-In Sampling at 7T"**  
*Dong-Hoon Lee*
- Cardiac** 1253 **T1, T2, and Fat Fraction Cardiac MR Fingerprinting: Preliminary Clinical Evaluation**  
*Olivier Jaubert, Gastao Cruz, Aurelien Bustin, Reza Hajhosseiny, Sohaib Nazir, Torben Schneider, Peter Koken, Mariya Doneva, Daniel Rueckert, Pier-Giorgio Masci, Rene M. Botnar, and Claudia Prieto*
- Editorial** 1266 **Editorial for "T1, T2, and Fat Fraction Cardiac Magnetic Resonance Fingerprinting: Preliminary Clinical Evaluation"**  
*Samuel W. Fielden*
- 1268 **Reproducibility of Aorta Segmentation on 4D Flow MRI in Healthy Volunteers**  
*Joe F. Juffermans, Jos J.M. Westenberg, Pieter J. van den Boogaard, Arno A.W. Roest, Hans C. van Assen, Roel L.F. van der Palen, and Hildo J. Lamb*

<i>Editorial</i>	<b>1280</b>	<b>Editorial for “Reproducibility of Aorta Segmentation on 4D Flow MRI in Healthy Volunteers”</b> <i>Andrew L. Wentland</i>
<b>Safety</b>	<b>1282</b>	<b>Ischemic Stroke Increased Gadolinium Deposition in the Brain and Aggravated Astrocyte Injury After Gadolinium-Based Contrast Agent Administration: Linear Versus Macrocyclic Agents</b> <i>Xin-Xin Huang, Run-Hao Jiang, Xiao-Quan Xu, Qing-Quan Zu, Fei-Yun Wu, Sheng Liu, and Hai-Bin Shi</i>
<i>Editorial</i>	<b>1293</b>	<b>Is gadolinium-enhanced magnetic resonance imaging possible without leaving a trace?</b> <i>Tim Leiner</i>
<b>Commentary</b>		
	<b>1295</b>	<b>Lifecycle of Gadolinium-Based Contrast Agents</b> <i>Michael Liu</i>

---

# JMRI INSTRUCTIONS FOR AUTHORS

The *Journal of Magnetic Resonance Imaging (JMRI)* is owned by the International Society for Magnetic Resonance in Medicine (ISMRM) and published by Wiley Subscription Services, Inc., a Wiley Company. *JMRI* is devoted to the timely publication of basic and clinical research, educational and review articles, and other information related to the diagnostic applications of magnetic resonance.

All manuscripts **must be submitted electronically**. For complete instructions on how to do so, go to <http://mc.manuscriptcentral.com/jmri> and follow the instructions for creating an account and submitting a manuscript.

## ■ TYPES OF MANUSCRIPTS

General **guidelines** for manuscript length and number of references and illustrations are as follows:

**Original Research:** up to 20 manuscript pages (5,000 words), 40 references, 10 figures and tables.

**Case reports:** up to 4 manuscript pages (1,000 words), 3 figures and 15 references, no abstract.

**Reviews:** up to 30 manuscript pages (7,500 words), 100 references, 15 figures and tables.

**Editorial/commentary:** most of these are solicited, 700-900 words 10 references (for editorials including a dummy reference for the paper being commented upon and only a rare figure).

**Guidelines:** up to 4 manuscript pages (1,000 words) and 10 references, no abstract.

**Letters to the Editor:** up to 500 words, 10 references, one figure/table.

*JMRI* encourages authors to share the data and other artifacts supporting the results in the paper by archiving it in an appropriate public repository. Authors should include a data accessibility statement, including a link to the repository they have used, in order that this statement can be published alongside their paper.

## Reporting Standards

Authors of systematic reviews and meta-analyses are advised to strictly adhere to the PRISMA statement (Preferred Reporting items for Systematic Reviews and Meta-Analyses), [www.prisma-statement.org](http://www.prisma-statement.org).

Authors of diagnostic accuracy studies are advised to strictly adhere to the STARD statement (STAndards for the Reporting of Diagnostic accuracy studies) <http://www.stard-statement.org/>

Authors of clinical trials are advised to strictly adhere to the CONSORT statement (CONSolidated Standards of Reporting Trials). <http://www.consort-statement.org/>

## NOTE

The instructions that follow address preparation of **INITIAL** manuscript submissions and resubmissions intended for review and possible publication in *JMRI*. Instructions for preparation and submission of **REVISED** manuscripts intended for possible publication in *JMRI* are included in decision notification letters that are sent to authors **AFTER** peer review. Authors preparing **REVISED** manuscripts should refer to the instructions and checklist provided in their decision notification letter.

## ■ MANUSCRIPT ORGANIZATION

Original writings will be accepted with the understanding that they are contributed solely to *JMRI*. Please ensure that all pages of the manuscript (including the reference section) are double-spaced and in 12-point type, with at least 2.5 cm margins. Acceptable typefaces include Arial, Times New Roman, and Bookman Old Style.

Each manuscript component should begin on a new page in this order:

**Full Title Page with acknowledgments (upload as a SEPARATE file when submitting manuscript)**

**Title/Abstract/Keywords**

**Text**

**References**

**Tables (each on a separate page)**

**Figure Legends**

**Figures**

Number all manuscript pages in the upper right corner, beginning with the abbreviated title page. Do this even though the system also supplies page numbers in the PDF view of the submission after it is uploaded.

**Double-Blinded Review:** To maintain anonymity during the review process, reviewers receive manuscripts with no authors' names listed to ensure unbiased, double-blinded review.

Instead of providing the authors' names and affiliations in the main manuscript file, please do so on a separate title page file. Do not give names of authors or their affiliations in the main manuscript text, on the figures or tables, or in the acknowledgments and disclosures. In the body of the text make a conscious effort to use phrasing that does not reveal the identity of the authors. For example, instead of using phrases such as "In our study. . ." followed by a reference number identifying your group, use phrases such as "In a previous study...". After review, the original wording can be restored.

When submitting your manuscript, (1) upload the full title page as the first file (designate it as "Title Page") and (2) upload the manuscript (i.e., all elements except the full title page) as the next file(s) (designate them as Main Document or Image [as appropriate]). NOTE: If you have uploaded the files correctly, you WILL NOT be able to view the full title page in the PDF and HTML proofs of your manuscript. However, the editor and editorial office can easily view the author information during the pre-review check and reviewer selection stages.

## Full Title Page

**Title:** Do not use registered/trademark terms in the manuscript title. Use their generic equivalents instead. Do not use all but the most familiar abbreviations. Avoid the use of such terms as CMR, MRE, as they may have more than one meaning.

**Author Names and Degrees:** Provide first names, middle initials, and highest academic/technical degree(s) of all authors (e.g., MD, PhD, MS, BS, RN, RT). Please do not list honorary degrees or fellowships. Co-first authors and corresponding authors should be specified on the title page and cover letter.

**Author Affiliations:** Please list departmental/institutional affiliations for authors. Please tie each author to the appropriate department(s)/institution(s) using consecutive, superscripted Arabic numbers.

**Corresponding Author Info:** Provide the name, street address, telephone and fax numbers, and the e-mail address of the corresponding author(s). Co-corresponding authors are allowed.

**Acknowledgments:** Use this section to acknowledge individuals who have provided personal assistance. Please give full names of all individuals mentioned in this section.

**Grant Support:** List grant support, if any, on the full title page.

**Running Title:** At the bottom of the page, please include a short running title of 40 characters/spaces or less.

## Terminology

Avoid the use of subjective terms like high resolution, fast, high field. State the resolution or field strength at the beginning of your paper then call it "high" later in the paper.

Define each used abbreviations within each section of the manuscript (abstract, body, and figures) or provide an abbreviation key. Avoid abbreviations in the title.

## Abstract/Keywords

**Abstract:** An abstract of no more than 300 words must be submitted with each manuscript. Include the abstract in the text file AND in the appropriate field of the website. Abstracts submitted with Original Research papers must be structured as follows: BACKGROUND, PURPOSE or HYPOTHESIS, STUDY TYPE (retrospective/prospective/longitudinal/ casecontrol/cohort etc.), POPULATION or SUBJECTS or PHANTOM or SPECIMEN or ANIMAL MODEL (type and numbers), FIELDSTRENGTH/SEQUENCE, ASSESSMENT (what? By whom? How? What criteria?), STATISTICAL TESTS, RESULTS (must have numerical data and statistical testing for each phrase), DATA CONCLUSION (conclusion is based on the author's results only). Abstracts submitted for Review Articles follow an unstructured format and should state in a single paragraph what was done, what was found, and what was concluded. Other types of papers should not have an abstract. There are no abstracts for case reports or editorials.

**Keywords:** Every manuscript must include a list of three to six key words below the abstract. These words will assist indexers who will then classify the paper under specific subject headings for future indexes.

## Text

Authors must use Microsoft Word for preparation of text files. The text of observational and experimental studies is arranged in sections with the headings as follows: Introduction, Materials and Methods, Results, and Discussion. Long papers may need subheadings in both the Materials and

# INSTRUCTIONS FOR AUTHORS

## CONTINUED

Methods and the Results sections to clarify their content. The discussion section should be entirely in narrative form with no subheadings. Begin last paragraph of Discussion with "In conclusion." Do not number sections.

**Introduction:** Set the stage for why you did what you did. Never state "we are the first", "not previously done," etc. The introduction should end with a clearly stated purpose of the study. This should be similar to the purpose stated in your abstract. Do not provide an overview of your methods anywhere, especially at the end of your introduction. Give only strictly pertinent references and do not review the subject extensively.

**Materials and Methods:** Must include a statement about IRB/REB approval and informed consent or the waiver thereof at the beginning of this section. For animal studies, a statement about animal care committee approval should be provided. Describe your selection of the observational or experimental subjects (patients or experimental animals, including controls) clearly. Describe in detail your inclusion and exclusion criteria and the number of patients excluded for each reason. Identify the method, instrumentation (manufacturer's name and address in parentheses), and procedures in enough detail to allow other workers to reproduce the results. For subjective observations, always provide the exact years of experience of the observer. Provide assessments of variability in subjective assessments and measurements. Do not include the name of the institution where the work was performed, either within the text or at the top of each manuscript page. Give references to established methods, including statistical methods that have been published but are not well known; describe new or substantially modified methods. Include numbers of observations. Statistical tests used should be a subsection at the end of your methods section, and you should set the level of your type I and type II errors when appropriate. If one or more of the co-author(s) work for a commercial entity, discuss the manner in which potential conflicts of interest were minimized.

**Results:** Present the results in logical sequence in the text, tables, and illustrations. Do not repeat in the text all the data in the tables and/or illustrations; summarize only important observations. Be progressively granular. Do not repeat the statistical tests listed in the methods section. Always provide precise p values when you say "significant" or "non-significant". If you conclude the negative - there is no association - provide confidence intervals or a power analysis. Avoid descriptive adjectives.

**Discussion:** This portion of the paper does not repeat your findings but puts your findings into context. Often the first paragraph of the discussion highlights the most important findings of your research. Emphasize the new and important aspects of the study and conclusions that follow from them. State when your results are similar to others and when they are different. If they are different, state why you think this occurred. Do not repeat in detail the data given in the Results section. Do not repeat numerical results in your discussion. Do not reference figures or tables. Provide reasons for using your techniques and evaluate the limitations of these techniques. Link the conclusions with the goals of the study, but avoid unqualified statements and conclusions that are not supported completely by the data. Do not add any new data that was not mentioned in your results section. Avoid claiming priority and alluding to work that has not been completed. Avoid self-aggrandizement or hyperbole, few studies change how medicine is practiced. Be concerned about generalizability, and do not claim that your findings might be applied to different populations. State new hypotheses when warranted, but clearly label them as such. Recommendations, when appropriate, may be included, but these should be modest, and well considered. Subheadings in the discussion are encouraged. The penultimate paragraph of your discussion should be a study limitations paragraph. This paragraph should have a sublabel of "LIMITATIONS". This may include limitations of your sequence or processing, but should be focused to a greater degree on the limitations of your study design. The discussion should end with a conclusion. This paragraph should have a sublabel of "CONCLUSION". This conclusion is based on your results, put into context of prior authors results and your study limitations. Discussions should not provide an overview of a disease, treatment or technique, but provide just enough information for the reader to put the findings into context. Discussions should be commensurate in length with the complexity of your results, and in general should be brief.

## References

Number references consecutively in the order in which they were first mentioned; place the numbers between parentheses for in-text citations. Only literature that is published or in press (with the name of the publication known) may be numbered and listed. Abstracts and letters to the editor may be cited, but they must be less than 3 years old and identified as such. Other material (manuscripts submitted, unpublished data, personal communications, etc.) should only be referred to in the text, as in the following example: (Smith J, unpublished data). If the owner of the unpublished data or personal communication is not an author of the manuscript under review, a signed statement is required verifying the accuracy of the attributed information and agreement to its publication. Anything which is not common knowledge to the presumed reader must be referenced. If you state that something is controversial, authors disagree, or the literature is unclear, 2 to 3 references should be provided for that statement. If you say "studies", more than one reference is needed. Most other statements rarely require more than one reference. Always reference the original source. JMIR prefers references of non-review type papers.

The abbreviations used for periodicals cited in the references should follow the style of *Index Medicus*. For **journal articles**, list surnames and initials of all authors when six or less, such as:

1. Geurts JJG, Barkhof F, Castelijns JA, Uitdehaag BMJ, Polman CH, Pouwels PJW. Quantitative H-MRS of healthy human cortex, hippocampus, and thalamus; Metabolite concentrations, quantification precision, and reproducibility. *J Magn Reson Imaging* 2004;20:366-371.

When seven or more authors are listed, only the first three names need to be identified, followed by "et al," such as:

2. Schwickert HC, Roberts TP, Shames DM, et al. Quantification of liver blood volume: comparison of ultra short TI inversion recovery echo planar imaging (ULSTIR-EP1), with dynamic 3D-gradient recalled echo imaging. *Magn Reson Med* 1995;34:845-852.

For online only articles, or articles "in press", the DOI (Digital Object Identifier) provides a persistent link to the article:

3. Madelin G and Regatte RR. Biomedical applications of sodium MRI in vivo. 2013; in press. doi: 10.1002/jmri.24172

In the case of books, the authors of a chapter, title of the chapter, editor(s), title of the book, edition, city, publisher, year, and specific pages must be provided. For the complete book, the number of pages is given instead, e.g., 512 p.

4. Desnick R, Ioannou YA, Eng CM.  $\alpha$ -Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. *The metabolic and molecular bases of inherited disease*, 8th edition. New York: McGraw-Hill; 2001. p 3733-3774.

5. Feller W. *An introduction to probability theory and its applications*, 2nd edition. New York: John Wiley and Sons Inc; 1968. 48 p.

**Abstracts, editorials, and letters to the editor** should be noted as such, giving page number range or abstract number in parentheses at end of reference.

For meetings other than ISMRM, give the author list, presentation title, meeting title, sponsoring organization name, month, day(s), year of meeting, location, page number range or abstract number, and if the proceedings have been published, give the publisher name and location:

6. Rodenburg JB, Smink J, Salverda P, et al. Slice tracking and navigator gating provide good image quality without the need for breath-holding in lung imaging. In: *Proceedings of the 8th Annual Meeting of ISMRM*, Denver, 2000. (abstract 954).

Please be sure that all documentation is accurate.

*JMRI* requires authors to cite data in the same way as article, book, and web citations in their reference list. Data citation is appropriate for data held within institutional, subject focused, or more general data repositories. It is not intended to take the place of community standards such as in-line citation of GenBank accession codes.

## Tables

Tables should be numbered in Arabic numerals in the order of their appearance in the text and should have a brief title. All abbreviations used in the table should be explained in a footnote. Each table should be structured with three horizontal lines and no vertical lines or boxes.

## Figure Legends

A legend must be supplied for each illustration and should not duplicate text material. All figure legends should appear collectively on one or more pages at the end of the text file, and each legend should also appear below the corresponding figure.

## Figures

Figures should be limited to those required to show the essential features described in the paper. Excessive illustrations encroach on the total space available in *JMRI* to the detriment of the publication. Images to be combined into one cut, such as anteroposterior and lateral views, should be the same height to facilitate reproduction. Images should correspond in appearance to the tonal relations of the original image (with the patient's right to the observer's left for coronal images; axial images should employ the "view from below").

Figures should be numbered in the order in which they are mentioned in the text. All figures should be labeled a, b, c, etc. in the upper left corner,

# INSTRUCTIONS FOR AUTHORS CONTINUED

but not within the figure frame. Symbols, letters, and numbers must be legible after reduction, with the smallest data points no less than 1.5- to 1.7-mm high. Images need to be cropped and all irrelevant parts removed. Figure parts should be limited to 10.

For each accepted manuscript, the Journal provides print color free of charge. Authors are encouraged to submit color illustrations that highlight the text and convey essential scientific information. For best reproduction, bright, clear colors should be used. Please place your color images against a white background wherever possible. Please contact the production editor at [jmri@wiley.com](mailto:jmri@wiley.com) for further information.

It is extremely important that authors check the accuracy of any keys on the images before the final versions are sent to the Editorial Office. For additional information regarding preparation of figures, see "Electronic Submission of Graphics" in these instructions.

## ■ OTHER MANUSCRIPT ELEMENTS

### Units & Abbreviations

Radiation measurements and laboratory values should be given in the *International System of Units (SI)* (resources: *SI Units in Radiation Protection and Measurements*, NCRP Report no. 82 [August 1985]; "Now Read This: The SI Units Are Here," *JAMA* 1986;255:2329-2339). Blood pressure should still be reported in millimeters mercury. Abbreviations should be spelled out when first used in the text, such as "cerebrospinal fluid (CSF)." Magnetic resonance terminology should conform to the *Glossary of MR Terms* published by the American College of Radiology. Laboratory slang, clinical jargon, and uncommon abbreviations should be avoided. Discussion of previous literature and material presented must be restricted to the significant findings.

### Informed Consent

Manuscripts reporting the results of experimental studies on human subjects must include a statement to the effect that informed consent was obtained after the nature of the procedure(s) had been fully explained.

The maintenance and care of experimental animals to provide humane treatment and to ensure reliable results are described in the National Institutes of Health guidelines for use of laboratory animals. Authors are advised to comply with these guidelines and to acknowledge such compliance in their manuscripts.

### Data Availability

Manuscripts on AI and related topics should include a statement indicating the specific web address or repository where the underlying code may be accessed.

### Author Responsibility and Exclusive Submission

Authors must be certain that no manuscript on the same or similar material has been or will be submitted to another journal by themselves or others at their institution before their work appears in *JMRI*. The submission by authors of similar material to advertising media must be indicated at the time *JMRI* receives the manuscript.

## ■ ADDITIONAL GUIDELINES

### Financial Interest

Authors must describe any direct or indirect financial interest they may have in the subject matter of a submitted manuscript, and must authorize the ISMRM to publish this financial disclosure with the article if deemed appropriate. The Financial Disclosure policy of the ISMRM is as follows:

"Each author shall describe (a) any direct financial interest which that author has in the subject matter discussed in the submitted manuscript, and (b) any affiliation or financial involvement which that author has with or in any organization with a direct financial interest in the subject matter discussed in the submitted manuscript. Such information will be held in the confidence of the journal editor during the review process. If necessary, in the editor's view, this information may be shared with reviewers after discussion between the editor and author. The author shall grant permission for the ISMRM to publish the financial information described above, or an appropriate summary thereof, with the manuscript if the manuscript is accepted for publication."

## Electronic Submission of Graphics

Images submitted must be in Tagged Image File Format (TIFF) or Encapsulated PostScript (EPS). They may be submitted from either a MS-DOS or Macintosh system. PowerPoint figures are acceptable, but are not preferred for best quality in print. If figures are in PowerPoint, Adobe Photoshop, or EPS, it is recommended to use Aldus Freehand or QuarkXPress. Figures prepared in Word, Excel, Microsoft Publisher, Lotus 123 and Corel Draw are not acceptable. All images must be saved and submitted in final size; all cropping and manipulation must be completed before the images are submitted to the publisher. Figures should not exceed 8-in (21.6-cm) in height; figure widths should be 3-in (8.25-cm) for 1 column, 5-in (13-cm) for 1.5 columns, or 6-in (17.15-cm) for 2 columns.

Rapid Inspector™ gives authors of scientific, technical and medical journals a resource for certifying their illustrations prior to submission. Utilizing this software will ensure that your graphics are suitable for print production. To download this journal's free Rapid Inspector software, please visit <http://rapidinspector.cadmus.com/wi/index.jsp>.

Minimum figure resolutions are as follows: 1200 dots per inch (dpi) for line art; 600 dpi for color, and 300 dpi for black and white. To ensure good reproduction online and in print, the minimum black value on a halftone scan (highlight) should be 4% black. The maximum value (shadow) should be no higher than 95%. Avoid the use of fine lines (point and below) for graphs and charts. Use only Adobe Type 1 fonts in creating images, and limit the number of fonts used. Do not reletter images in Photoshop. If relettering must be done, import the image into either Freehand or QuarkXPress and reletter, then make an EPS file. Make sure all scanned images are "clean." Look for and clean up dust specks, scratches, tape marks, and anything that is not part of the actual image. Files generated in Freehand should be saved in EPS format.

If QuarkXPress is used for image assembly, please follow these guidelines:

(a) After creating the image, adjust the page size in the "Document Setup" window in the pull-down menus. (b) Modify the page size to be only slightly larger than the image size. If the image is 20 pica wide by 10 pica deep, make the page size 22 pica wide by 12 pica deep and center the image within the page. (c) Once this has been done, save the page as an EPS file by doing a "Save As. . ." from the pull-down menu. (d) Each image must be submitted as a separate EPS file. Do not submit an entire Xpress file saved in EPS format.

## Submission of Supporting Information

Supporting Information may include (but is not limited to) video clips, large sections of tabular data, program code, or electronic graphical files that are otherwise not suitable for print media. When submitting material for consideration please follow the guidelines below.

**Peer review:** Supporting Information must be submitted at the time of peer review.

**Acceptance and electronic submission:** Once material has been accepted by the editors, it must be submitted in electronic form. Please note that Supporting Information is not copyedited or formatted in any way by the Publisher.

**Data file types:** There are no restrictions on filetypes of the data that you submit. Please keep in mind, however, that the more universal the filetype the more accessible to the community. The use of popular compression protocols is highly encouraged. If your material is presented in PostScript format, the submission of an accompanying Adobe Acrobat PDF file is encouraged, in that event both formats will be offered to the journal's readers. In cases where PDF files do not accompany a PostScript file, only the Postscript will be offered.

**Publication Access:** Supporting Information for published articles can be accessed through the online version of the article, which is available at [onlinelibrary.wiley.com](http://onlinelibrary.wiley.com).

## ■ BOOK REVIEWS

Anyone who would like to help in reviewing books for *JMRI* should contact

Diego R. Martin, MD, PhD  
*JMRI* Associate Editor, Book Reviews  
Professor and Head, Radiology Department  
University of Arizona  
University Medical Center  
1501 North Campbell Avenue  
PO Box 245067  
Tucson, AZ 85724  
E-mail: [dmartin@radiology.arizona.edu](mailto:dmartin@radiology.arizona.edu)

# INSTRUCTIONS FOR AUTHORS CONTINUED

## ■ ACCEPTED MANUSCRIPTS

### Copyright Assignment and Authorship Criteria

Authors submitting a manuscript do so with the understanding that if it is accepted for publication, copyright in the article, including the right to reproduce the article in all forms and media, shall be assigned exclusively to the ISMRM. After the acceptance of their paper, authors will be provided instructions for completing an online copyright transfer agreement (CTA). Articles cannot be published until the publisher has received the appropriate signed license agreement from the authors. Once your article has been accepted and received by Wiley for production, the corresponding author will receive an email from Wiley's Author Services system which will ask them to log in and will present them with the appropriate license for completion.

JMRI requires that all authors and co-authors satisfy the authorship criteria described by the International Committee of Medical Journal Editors (ICMJE), which state: "Authorship criteria should be based on: (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3."

### Note to Contributors on Deposit of Accepted Version

Authors are permitted to self-archive the peer-reviewed (but not final) version of the Contribution on the Contributor's personal website, in the Contributor's company/institutional repository or archive, and in certain not for profit subject-based repositories such as PubMed Central as listed at the following website: <http://olabout.wiley.com/WileyCDA/Section/id-820227.html>, subject to an embargo period of 12 months for scientific, technical and medical (STM) journals and 24 months for social science and humanities (SSH) journals following publication of the final Contribution.

There are separate arrangements with certain funding agencies governing reuse of this version as set forth at the following website: <http://www.wiley.com/go/funderstatement>

The Contributor may not update the accepted version or replace it with the published Contribution."

### For Authors Choosing OnlineOpen

Choosing OnlineOpen makes your article open access and freely available to all on Wiley Online Library, including those who don't subscribe to the journal. OnlineOpen fulfills funding agency mandates that require grantees to archive the final version of their article. Wiley will also deposit your OnlineOpen article in PubMed Central and PMC mirror sites.

The cost for OnlineOpen is usually US\$3,000, which can be paid by the author, the author's funding agency, or the author's institution.

### Copyright and Open Access Licenses

Authors choosing OnlineOpen will retain copyright in their articles and will be offered a choice of creative commons licenses.

All Research Councils UK (RCUK), Wellcome Trust and Austrian Science Fund (FWF) funded authors will be directed to the Creative Commons Attribution license (CC-BY) [<http://creativecommons.org/licenses/by/3.0/>].

All other authors (non-RCUK and Wellcome Trust funded authors) are free to choose Creative Commons Attribution Non-Commercial (CC-BY-NC) [<http://creativecommons.org/licenses/by-nc/3.0/>], or Attribution-Non-Commercial-NoDerivs (CC-BY-NC-ND) [<http://creativecommons.org/licenses/by-nc-nd/3.0/>] license.

More information about open access license terms and conditions are available at the following website: <http://olabout.wiley.com/WileyCDA/Section/id-815641.html>.

### Compliant with Funder Mandates - Open Access Policies

OnlineOpen is fully compliant with open access mandates --- meeting the requirements of funding organizations where these apply, including but not limited to:

Research Councils UK: MRC, BBSRC, AHRC, ESRC, EPSRC, NERC, STFC  
The Wellcome Trust  
Austrian Science Fund  
Telethon Italy  
NIH  
The Howard Hughes Medical Institute (HHMI)

More information on funder mandates and open access policies are available at the following website: <http://olabout.wiley.com/WileyCDA/Section/id-406074.html>.

### Note to NIH Grantees

Pursuant to NIH mandate, Wiley-Blackwell will post the accepted version of contributions authored by NIH grant-holders to PubMed Central upon acceptance. This accepted version will be made publicly available 12 months after publication. For further information, see [www.wiley.com/go/nihmandate](http://www.wiley.com/go/nihmandate).

### Rights and Permissions

Direct quotations, tables, or illustrations taken from copyrighted material must be accompanied by written permission for their use from the publisher. The permission is presented as a footnote or addition to the legend and must provide complete information as to source. Photographs of identifiable persons must be accompanied by a signed release that indicates informed consent. Otherwise, the eyes must be blacked out to prevent identification.

Requests to use material that appears in JMRI and other permission inquiries should be submitted via the "Request Permissions" link on Wiley Online Library. Simply click on the link next to the article in question and follow the instructions.

### Proofs and Reprints

Proofs will be sent electronically to the corresponding author. Authors should indicate all corrections in an annotated PDF file.

To avoid delays in publication, proofs should be returned to the Production Editor at [jmri@wiley.com](mailto:jmri@wiley.com) within 48 hours of receipt.

Authors may order reprints by contacting the address provided in the proof package.

### General correspondence concerning JMRI may be directed to

Mark E. Schweitzer, MD, Editor-in-Chief, JMRI  
Wayne State University School of Medicine  
Health Science Drive  
Detroit, MI 48201-1928  
[jmrieditor@ismrm.org](mailto:jmrieditor@ismrm.org)

Sara Welliver, Managing Editor, JMRI  
201 Shannon Oaks Dr., Suite 124  
Cary, NC 27511  
Phone: (+1) (919) 650-1459 ext. 210  
[jmrieditorialoffice@gmail.com](mailto:jmrieditorialoffice@gmail.com)

### NIH Public Access Mandate

For those interested in the Wiley-Blackwell policy on the NIH Public Access Mandate, please visit our policy statement

For additional tools visit Author Resources - an enhanced suite of online tools for Wiley InterScience journal authors, featuring Article Tracking, E-mail Publication Alerts and Customized Research Tools.

- Permission Request Form
- The National Institutes of Health Public Access Initiative

Articles cannot be published until the publisher has received the appropriate signed license agreement from the authors. Once your article has been accepted and received by Wiley for production, the corresponding author will receive an email from Wiley's Author Services system which will ask them to log in and will present them with the appropriate license for completion.

### Other Resources

Common Mistakes Authors Make (PDF format)

### Production Questions?

JMRI Production  
E-mail: [JMRI@wiley.com](mailto:JMRI@wiley.com)